We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ADVANTECH SERVICE-IOT CO., LTD. TAIWAN BRAN

Download Mobile App





AstraZeneca COVID-19 Vaccine Phase 3 Trials Halted After Suspected Adverse Reaction in UK Participant

By HospiMedica International staff writers
Posted on 09 Sep 2020
Print article
Image: AstraZeneca COVID-19 Vaccine Phase 3 Trials Halted After Suspected Adverse Reaction in UK Participant (Photo courtesy of AstraZeneca).
Image: AstraZeneca COVID-19 Vaccine Phase 3 Trials Halted After Suspected Adverse Reaction in UK Participant (Photo courtesy of AstraZeneca).
AstraZeneca (Cambridgeshire, England) has halted a large Phase 3 study of its COVID-19 vaccine at dozens of sites across the US has due to a suspected serious adverse reaction in a participant.

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to STAT News, a number of different reactions can qualify as suspected serious adverse reactions, symptoms that require hospitalization, life-threatening illness and even death. An individual familiar with the matter told STAT News that the nature of the adverse reaction and when it happened were not immediately known, although the participant was expected to recover. It was also not clear in which clinical trial the adverse reaction occurred, although it appears to have taken place in the Phase 2/3 trial underway in the UK.

An AstraZeneca spokesperson told STAT News that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.” The spokesperson termed the pause as “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.” AstraZeneca is “working to expedite the review of the single event to minimize any potential impact on the trial timeline,” according to the spokesperson.

An individual familiar with the development told STAT News that a hold was placed on the trial out of “an abundance of caution.” Another individual familiar with the matter told STAT News that the finding was impacting other AstraZeneca vaccine trials underway, as well as the clinical trials conducted by other vaccine manufacturers.

Related Links:
AstraZeneca
University of Oxford



Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.